Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of
molecular alterations, and as such, long-term disease control requires multiple therapeutic …

In spite of the recent approval of new promising targeted therapies, the clinical outcome of
patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for …

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal
hematopoietic stem cell diseases arising from the bone marrow (BM), and approximately …

Despite considerable progress has been achieved in the treatment of acute myeloid
leukemia over the past decades, relapse remains a major problem. Novel therapeutic …

In the past few years, our improved knowledge of acute myeloid leukemia (AML)
pathogenesis has led to the accelerated discovery of new drugs and the development of …

Background Patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) have
limited treatment options. In preclinical models of AML, inhibition of the PD‐1/PD‐L1 axis …

Background Experience with immune checkpoint inhibitors (ICIs) in the treatment of acute
myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported …

Acute myeloid leukemia (AML) is a heterogeneous disease associated with various
alterations in T cell phenotype and function leading to an abnormal cell population …

Nucleoside-based drugs, recognized as purine or pyrimidine analogs, have been potent
therapeutic agents since their introduction in 1950, deployed widely in the treatment of …

Simple Summary Despite significant advancements, acute myeloid leukemia (AML) still
remains characterized by a dismal prognosis in too many patients, and oftentimes, a cure …